---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003572"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:20:11.610871+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Two Aclaris directors to depart at 2024 annual meeting

## Summary
- Director Andrew Powell resigns effective June 6, 2024; no disagreement cited.
- Director Bryan Reasons will not stand for re-election at June 6 annual meeting; no disagreement.
- No replacements announced for the two departing board members.

## SEC filing metadata
- accession: 0001558370-24-003572
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/acrs-20240314x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003572
- JSON: https://secwatch.observer/filing/0001558370-24-003572.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003572.txt

## Key facts
- Executive change
  Andrew Powell resigned as Director at Aclaris Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm
- Executive change
  Bryan Reasons departed as Director at Aclaris Therapeutics, Inc..
  - Action: not stand for re-election
  - Role: Director
  source text: Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.